Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Patients with large, complex, or giant incisional hernias often require advanced preoperative optimization to facilitate safe abdominal wall reconstruction and reduce postoperative complications. Several strategies are currently used in clinical practice, including botulinum toxin A injection, progressive preoperative pneumoperitoneum, and their combination. However, the optimal differentiated approach based on hernia characteristics and abdominal wall tissue deficiency remains unclear.
This study aims to compare the effectiveness and safety of different preoperative preparation strategies in patients with large postoperative ventral hernias and loss of abdominal wall domain. Outcomes of patients receiving botulinum toxin A, progressive preoperative pneumoperitoneum, combined preparation, or no specific preparation will be analyzed.
The study will evaluate operative feasibility, ability to achieve fascial closure, postoperative complications, recurrence, and overall treatment outcomes.
Large and giant incisional hernias remain a major challenge in abdominal wall surgery. In patients with loss of domain, reduced abdominal cavity volume, lateral muscle retraction, and soft tissue deficiency, standard hernia repair may be associated with high tension closure, respiratory compromise, abdominal compartment syndrome, wound complications, and recurrence.
Preoperative optimization techniques such as chemical component relaxation with botulinum toxin A and progressive preoperative pneumoperitoneum have been increasingly used to improve abdominal wall compliance and restore abdominal domain. Combined use of these methods may provide additional benefit in selected patients.
The present prospective comparative study is designed to assess a differentiated treatment strategy in which the method of preoperative preparation is selected according to clinical and anatomical characteristics of the hernia defect.
Participants will be allocated to one of the following groups:
Botulinum toxin A Progressive preoperative pneumoperitoneum Combined botulinum toxin A plus pneumoperitoneum No specific preoperative preparation
Primary and secondary outcomes may include technical feasibility of repair, need for component separation, successful fascial closure, perioperative morbidity, hospital stay, recurrence rate, and patient recovery.
The results of this study may help optimize patient selection and develop evidence-based algorithms for management of complex abdominal wall defects.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Botulinum Toxin A | Experimental | Preoperative chemical relaxation of the lateral abdominal wall muscles using botulinum toxin A before hernia repair. |
|
| Progressive Pneumoperitoneum | Experimental | Preoperative progressive pneumoperitoneum used to increase abdominal cavity capacity before reconstruction. |
|
| Combined Preparation | Experimental | Combination of botulinum toxin A and progressive preoperative pneumoperitoneum before surgery |
|
| Standard Preparation | Active Comparator | Patients undergoing surgical repair without specific preoperative optimization techniques. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Botulinum Toxin A (Botox ) | Drug | Preoperative injection of botulinum toxin A into the lateral abdominal wall musculature. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Successful Midline Fascial Closure Rate | Proportion of patients in whom tension-free primary fascial closure is achieved during abdominal wall reconstruction. | Intraoperative assessment |
| Measure | Description | Time Frame |
|---|---|---|
| Postoperative Complication Rate | Overall postoperative morbidity including surgical and medical complications classified by Clavien-Dindo | 30 days after surgery |
| Length of Hospital Stay | From operation to discharge (up to 30 days) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ochapovsky Regional Clinical Hospital No.1 | Recruiting | Krasnodar | Krasnodarskiy Kray | 350000 | Russia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Participants are assigned to one of four parallel groups according to predefined clinical and anatomical criteria: botulinum toxin A, progressive preoperative pneumoperitoneum, combined preparation, or no specific preoperative preparation.
Not provided
Not provided
Open-label study due to the nature of the interventions
Not provided
| Progressive Preoperative Pneumoperitoneum | Procedure | Gradual insufflation of the peritoneal cavity before surgery. |
|
| Combined Preoperative Preparation | Procedure | Combination of botulinum toxin A and progressive pneumoperitoneum. |
|
| Standard Preoperative Management | Other | Routine preparation without specific optimization techniques. |
|
| Hernia Recurrence Rate | 12 months after surgery |
| Need for Component Separation Technique | Intraoperative assessment |
| ID | Term |
|---|---|
| D019274 | Botulinum Toxins, Type A |
| ID | Term |
|---|---|
| D001905 | Botulinum Toxins |
| D008666 | Metalloendopeptidases |
| D010450 | Endopeptidases |
| D010447 | Peptide Hydrolases |
| D006867 | Hydrolases |
| D004798 | Enzymes |
| D045762 | Enzymes and Coenzymes |
| D045726 | Metalloproteases |
| D001426 | Bacterial Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D001427 | Bacterial Toxins |
| D014118 | Toxins, Biological |
| D001685 | Biological Factors |
Not provided
Not provided